Biological Activity of Propolis Ointment with the Addition of 1% Nanosilver in the Treatment of Experimentally-Evoked Burn Wounds.

apitherapy burns nanosilver propolis sulfadiazine

Journal

Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357

Informations de publication

Date de publication:
14 Jul 2021
Historique:
received: 05 06 2021
revised: 02 07 2021
accepted: 05 07 2021
entrez: 24 7 2021
pubmed: 25 7 2021
medline: 25 7 2021
Statut: epublish

Résumé

The main objective of this study was to assess the pharmacological efficacy of ointments containing 1% propolis and 1% nanosilver, compared to the conventional treatment of burn wounds. In the evaluation of the results, we used clinical observation of scars, microbiological examinations, pathomorphological examinations, and analysis of free radicals. The analysis of the experiment results concerning the therapeutic effectiveness of the propolis ointment revealed its wide-ranging antibacterial action (against Gram-positive and Gram-negative bacteria). The 1% propolis ointment was found to accelerate neoangiogenesis and epithelialization, have a positive effect on the healing of burn wounds, improve the cosmetic look of scars, and have no side-effects. The analysis of free radicals in burn wounds showed impressive activity of the 1% nanosilver ointment in the reduction of free radicals. No synergism of pharmacological activity of propolis and nanosilver was shown. A comparative evaluation of the acquired research material allows us to provide a favorable opinion on the topical treatment of burn wounds with 1% propolis. The obtained results show that the 1% propolis ointment reduces healing time, offers antimicrobial action, and has a positive effect on the normal process of scar formation.

Identifiants

pubmed: 34301074
pii: polym13142312
doi: 10.3390/polym13142312
pmc: PMC8309302
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nanotechnology. 2005 Oct;16(10):2346-53
pubmed: 20818017
Scand J Plast Reconstr Surg. 1984;18(1):119-26
pubmed: 6377481
Toxicol Lett. 2008 Jan 4;176(1):1-12
pubmed: 18022772
Chem Soc Rev. 2014 Mar 7;43(5):1501-18
pubmed: 24292075
J Basic Clin Pharm. 2014 Dec;6(1):29-34
pubmed: 25538469
Int J Biol Sci. 2012;8(4):512-21
pubmed: 22457606
West J Med. 2001 Sep;175(3):205-6
pubmed: 11527855
Br J Plast Surg. 1993 Oct;46(7):585-9
pubmed: 8252267
Biotechnol Adv. 2009 Jan-Feb;27(1):76-83
pubmed: 18854209
Burns. 2011 Nov;37(7):1192-201
pubmed: 21741176
Evid Based Complement Alternat Med. 2013;2013:356737
pubmed: 23762125
Clin Chim Acta. 2010 Dec 14;411(23-24):1841-8
pubmed: 20719239
Clin Dermatol. 2003 Jan-Feb;21(1):7-11
pubmed: 12609583
Lett Appl Microbiol. 2000 Aug;31(2):174-7
pubmed: 10972723
J Altern Complement Med. 2002 Feb;8(1):77-83
pubmed: 11890438
Molecules. 2013 Nov 21;18(11):14397-413
pubmed: 24284491
Phytomedicine. 2005 Mar;12(3):221-8
pubmed: 15830845
Water Res. 2014 Mar 1;50:350-8
pubmed: 24210505
J Ethnopharmacol. 1999 Mar;64(3):235-40
pubmed: 10363838

Auteurs

Jakub Staniczek (J)

Department of Gynecology, Obstetrics and Gynecologic Oncology, Medical University of Silesia, Markiefki 87, 40-211 Katowice, Poland.

Żaneta Jastrzębska-Stojko (Ż)

Department of Anesthesiology, Central Clinical Hospital, Medical University of Silesia in Katowice, Medyków 14, 40-752 Katowice, Poland.

Rafał Stojko (R)

Department of Gynecology, Obstetrics and Gynecologic Oncology, Medical University of Silesia, Markiefki 87, 40-211 Katowice, Poland.

Classifications MeSH